Inactive Instrument

Highlights Oragenics Inc Nyse

Equities

US6840232036

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	Mar. 05	CI
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	Feb. 05	CI
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	Dec. 27	CI
Oragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Oragenics Signs Cash, Share Deal to Acquire Odyssey Health's Neurological Drug Technology Pipeline	23-10-05	MT
Oragenics, Inc. entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	23-10-04	CI
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Oragenics to Develop Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05	MT
Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05	CI
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE	23-03-14	CI
Oragenics, Inc. Enters into an Exclusive Global License Agreement with Inspirevax Inc	23-03-01	CI
Oragenics, Inc. Enters into an Exclusive Global License Agreement with Inspirevax Inc to Develop Intranasal Covid Vaccine Candidate	23-03-01	CI
Oragenics Regains Compliance with NYSE American's Continued Listing Standards	23-02-03	MT
Reverse Split: 1 of 60	23-01-22	FA
Reverse Split: 1 of 60	23-01-22	FA
China's Reopening Plan Sparks Economic Recovery Hopes, Lifts Exchange-Traded Funds, Equity Futures Premarket Tuesday	22-12-27	MT
Oragenics Says Study of Intranasal COVID-19 Vaccine Candidate Shows No Toxicity Signals; Shares Jump	22-12-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oragenics Inc Nyse

Equities

US6840232036

Highlights

Filters